Here are three things to know.
1. Zilretta is administered as an intra-articular injection.
2. The non-opioid drug is intended to provide pain relief for patients with moderate to severe OA knee pain over a 12-week period.
3. Flexion expects Zilretta to hit the market by the end of the month.
More articles on supply chain:
FDA commissioner: High drug prices are a ‘public health concern the FDA should address’
Judge ruling allows drug ‘price gouging’ law to take effect in Maryland
Rite Aid names former Walgreens executive as president, COO
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
